Key facts
- This page summarizes Emiko Higashi's Form 3 filing for TAKEDA PHARMACEUTICAL CO LTD (TAK).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 06:16.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
Includes 12,800 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on the following schedule: June 1, 2026 (3,100 shares), June 1, 2027 (3,400 shares), June 1, 2028 (3,200 shares) and upon conclusion of the director's board service (3,100 shares).
Footnote F2
Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Footnote F3
Vests upon conclusion of the director's service on the board.
SEC remarks
Exhibit 24 Power of Attorney